First clinical postmarketing experiences in the treatment of epilepsies with brivaracetam: a retrospective observational multicentre study.

Katja MenzlerPeter Michael MrossFelix RosenowSusanne Schubert-Bast Laurent Maximilian WillemsFelix ZahnertIlka ImmischSven FuestFelix von PodewilsRhina KunzMartin HirschTamara MuellerJustus MarquetandYaroslav WinterLisa LangenbruchMichal CicanicStefan BeyenburgAdam StrzelczykSusanne Knake

Published in: BMJ open (2019)

The present study shows that results of the phase III studies on BRV match data from real life clinical settings. Brivaracetam seems to be a useful alternative in patients who have suffered adverse effects while taking LEV.

Keyphrases

phase iii
end stage renal disease
ejection fraction
newly diagnosed
open label
chronic kidney disease
mental health
prognostic factors
electronic health record
big data
randomized controlled trial
cross sectional
placebo controlled
study protocol